Travere Therapeutics Inc
(TVTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 164,859 | 114,449 | 81,732 | 74,787 | 62,898 |
| Cost of Goods | 1,585 | 1,521 | 4,679 | 2,553 | 1,626 |
| Gross Profit | 163,274 | 112,928 | 77,053 | 72,234 | 61,272 |
| Operating Expenses | 138,928 | 126,099 | 120,406 | 133,524 | 118,047 |
| Operating Income | 24,931 | -12,650 | -42,674 | -60,737 | -56,149 |
| Interest Expense | 2,751 | 2,846 | 2,857 | 2,817 | 2,777 |
| Other Income | 3,534 | 2,761 | 4,344 | 3,214 | 4,090 |
| Pre-tax Income | 25,714 | -12,735 | -41,187 | -60,340 | -54,836 |
| Income Tax | 8 | 20 | 39 | -72 | -84 |
| Net Income Continuous | 25,706 | -12,755 | -41,226 | -60,268 | -54,752 |
| Net Income Discontinuous | 0 | 0 | 0 | 4 | -59 |
| Net Income | $25,706 | $-12,755 | $-41,226 | $-60,264 | $-54,811 |
| EPS Basic Total Ops | 0.29 | -0.14 | -0.47 | -0.71 | -0.70 |
| EPS Basic Continuous Ops | 0.29 | -0.14 | -0.47 | -0.70 | -0.70 |
| EPS Diluted Total Ops | 0.28 | -0.14 | -0.47 | -0.71 | -0.70 |
| EPS Diluted Continuous Ops | 0.25 | -0.14 | -0.47 | -0.70 | -0.70 |
| EPS Diluted Before Non-Recurring Items | 0.28 | -0.14 | -0.47 | -0.73 | -0.70 |
| EBITDA(a) | $40,719 | $1,366 | $-29,872 | $-51,456 | $-44,910 |